Table 5.
Case fatality rates in this study in relation to published reports
| Patient cohort | Number of patients | Setting | Case fatality rate | |
|---|---|---|---|---|
| Current study | Multiple myeloma | 100 | Inpatient and outpatient | 22% |
| Lee et al. (11) | All cancer patients | 800 | Inpatient and outpatient | 28% |
| Robilotti et al. (7) | All cancer patients | 423 | Inpatient and outpatient | 12% |
| Miyashita et al. (13) | All cancer patients | 334 | Inpatient and outpatient | 11% |
| Mehta et al. (10) | All cancer patients | 218 | Inpatient and outpatient | 28% |
| Mehta et al. (10) | Hematologic malignancy subcohort | 54 | Inpatient and outpatient | 37% |
| Dai et al. (2) | All cancer patients | 105 | Inpatient and outpatient | 11% |
| Cook et al. (9) | Multiple myeloma | 75 | Inpatient and outpatient | 54.7% |
| Malard et al. (12) | Hematologic malignancy | 25 | Inpatient | 36% |
| Docherty et al. (18) | All patients | 20,133 | Inpatient | 26% |
| Richardson et al. (3) | All patients | 5,700 | Inpatient | 21% |
| Goyal et al. (19) | All patients | 393 | Inpatient | 10% |
| Deng et al. (20) | All patients | 82,719 | All | 1%–8% |
| Guan et al. (1) | All patients | 1,099 | All | 1.4% |
| Johns Hopkins University CSSE COVID-19 mapa | All COVID-19–positive cases | ∼299,000 | All | 6% |
aCenter for Systems Science and Engineering (CSSE) at Johns Hopkins University COVID-19 map for cumulative number of cases and deaths on April 30, 2020 (https://coronavirus.jhu.edu/map.html).